SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Nusano's Ion Source and particle accelerator for creating radioisotopes at a facility in Salt Lake City.
Radiopharmaceuticals
The future of radiopharma is being built by nuclear geeks in SLC
Nusano will bring a massive new radioisotope facility in Salt Lake City online by the end of the year, establishing a supply of starting materials for the next generation of radiopharmaceuticals.
May 18, 2026
 · 
6 min read
 · 
Annalee Armstrong
Stairs in sky With Light
Pancreatic cancer
Can Revolution’s ‘miracle’ pancreatic cancer drug be topped? Immuneering, Actuate say yes
Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech’s heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve on that result with increased tolerability—and more time for patients.
May 18, 2026
 · 
7 min read
 · 
Heather McKenzie
Close up shot red darts arrows in the target center on dark blue sky background. Business target or goal success and winner concept.
Gene therapy
4 spaces primed for the next wave of gene therapies
The recent approval of Regeneron’s Otarmeni underscores the maturation of gene therapies across a range of diseases. Here, BioSpace reviews genetic medicines in development for the central nervous system, retinal, cardiac and neuromuscular diseases.
May 18, 2026
 · 
8 min read
 · 
Andrea Park
AI robotic head gazes at hand holding scales on dark blue background. Ethical decision-making, fairness, and balance in artificial intelligence concept. Low polygonal abstract vector illustration
Opinion
FDA alignment is critical to serving the rare disease community. AI can help
The FDA has introduced models intended to accelerate rare disease drug development, but recent reversals of guidance from the agency speak to a lack of clarity in its implementation. AI can help focus this process.
May 18, 2026
 · 
4 min read
 · 
Rahul Gupta
Illustration of young woman standing in front of exit door
FDA
Interim CDER head Høeg is out days after Makary: report
Just a few days after FDA Commissioner Makary resigned, ally Tracy Beth Høeg is also leaving the agency. Her departure comes amid reports of tension over a commissioner’s voucher for Sanofi’s diabetes drug.
May 15, 2026
 · 
2 min read
 · 
Gabrielle Masson
Image of San Francisco from San Francisco Headlands
Job Trends
Employment and funding growth fell in 2025: California Life Sciences report
California life sciences jobs declined 1.8% last year, according to the new California Life Sciences sector report. While National Institutes of Health funding and venture capital investment rose, their growth slowed from the previous year.
May 15, 2026
 · 
2 min read
 · 
Angela Gabriel
Sorting garbage concept. Cropped photo of paper thash. Crumple paper falling to the recycling bin
Drug Development
Genmab drops 2 antibody assets, including another ProfoundBio ADC
Rina-S is the last candidate standing from Genmab’s $1.8 billion ProfoundBio acquisition two years ago, with the Danish drugmaker ending development of another clinical program stemming from the buyout.
May 15, 2026
 · 
2 min read
 · 
Gabrielle Masson
Vector illustration. Product recall.
Manufacturing
Sun Pharma recalls cancer drug after finding glass particles in some vials
A batch of a chemotherapy product made at a Sun facility with a history of quality and compliance issues is being withdrawn from the U.S. market.
May 15, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Brain shaped maze. Conceptual image of science and medicine. 3D illustration.
Drug Development
Biogen’s Alzheimer’s results bolster tau theory—and Denali’s next gen candidate
If Biogen has shown that tau can impact cognition, Denali’s technology—validated with an FDA approval in Hunter syndrome—could ensure the medicine gets where it needs to be for the greatest therapeutic impact, analysts said.
May 15, 2026
 · 
3 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS